Article
Afatinib restrains K-RAS-driven lung tumorigenesis.
Science translational medicine - 20 Jun 2018
Moll Herwig P, Pranz Klemens, Musteanu Monica, Grabner Beatrice, Hruschka Natascha, Mohrherr Julian, Aigner Petra, Stiedl Patricia, Brcic Luka, Laszlo Viktoria, Schramek Daniel, Moriggl Richard, Eferl Robert, Moldvay Judit, Dezso Katalin, Lopez-Casas Pedro P, Stoiber Dagmar, Hidalgo Manuel, Penninger Josef, Sibilia Maria, Győrffy Balázs, Barbacid Mariano, Dome Balázs, Popper Helmut, Casanova Emilio
Abstract excerpt
On the basis of clinical trials using first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), it became a doctrine that V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-RAS) mutations drive resistance to EGFR inhibition in non-small cell lung cancer (NSCLC). Conversely, we provide evidence that EGFR signaling is engaged in K-RAS-driven lung tumorigenesis in humans and in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.